The First-week Proliferative Response of Peripheral Blood PD-1
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
CD8-Positive T-Lymphocytes
/ immunology
Cell Proliferation
/ drug effects
Female
Flow Cytometry
Humans
Lymphocyte Count
Male
Middle Aged
Molecular Targeted Therapy
Neoplasms
/ blood
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
ROC Curve
Survival Analysis
Time Factors
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 04 2019
01 04 2019
Historique:
received:
10
05
2018
revised:
23
08
2018
accepted:
07
01
2019
pubmed:
17
1
2019
medline:
12
5
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
To investigate blood-based dynamic biomarkers that predict responses to anti-programmed cell death protein 1 (PD-1) therapy in solid tumors. Preplanned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631) in patients with metastatic or refractory thymic epithelial tumors (TETs; A higher fold-change in the percentage of Ki-67 The proliferative response of peripheral blood PD-1
Identifiants
pubmed: 30647082
pii: 1078-0432.CCR-18-1449
doi: 10.1158/1078-0432.CCR-18-1449
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Programmed Cell Death 1 Receptor
0
Banques de données
ClinicalTrials.gov
['NCT02607631']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2144-2154Commentaires et corrections
Type : ErratumIn
Informations de copyright
©2019 American Association for Cancer Research.